{"filing":{"accession_number":"0001628280-26-048347","cik":"0001253689","ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"cbio-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026048347/cbio-20260714.htm"},"events":[{"id":18200,"run_id":16352,"accession_number":"0001628280-26-048347","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Crescent Biopharma entered into an underwriting agreement on July 14, 2026 to issue 8,094,793 ordinary shares at $14.50 per share plus 525,897 pre-funded warrants, with expected net proceeds of approximately $115.9 million (or $133.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly discloses the offering price, number of shares, and use of proceeds to fund operations into the second half of 2028, making this a material capital-raising event typical of dilutive equity issuances.","company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16938,"accession_number":"0001628280-26-048347","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Crescent Biopharma entered into an underwriting agreement on July 14, 2026 to issue 8,094,793 ordinary shares at $14.50 per share plus 525,897 pre-funded warrants, with expected net proceeds of approximately $115.9 million (or $133.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly discloses the offering price, number of shares, and use of proceeds to fund operations into the second half of 2028, making this a material capital-raising event typical of dilutive equity issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:58:38.505589+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16938,"accession_number":"0001628280-26-048347","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Crescent Biopharma entered into an underwriting agreement on July 14, 2026 to issue 8,094,793 ordinary shares at $14.50 per share plus 525,897 pre-funded warrants, with expected net proceeds of approximately $115.9 million (or $133.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly discloses the offering price, number of shares, and use of proceeds to fund operations into the second half of 2028, making this a material capital-raising event typical of dilutive equity issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:58:38.505589+00:00","company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","filing_date":"2026-07-15"}]}